Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.44 |
| ▸ | ITPR3 | Q14573 | 1/20 | 0.42 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26079101 | 1.00 | LPAR3 (0.44) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL19237471 | 1.00 | LPAR3 (0.44) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL14727906 | 0.96 | LPAR3 (0.41) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL17052326 | 0.92 | ITPR3 (0.49) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL23631720 | 0.87 | ITPR3 (0.47) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL15935828 | 0.85 | LPAR3 (0.48) | LPAR3LPAR2LPAR1PLA2G2ACYP3A4 | |
| SCHEMBL10178024 | 0.85 | LPAR3 (0.48) | LPAR3LPAR2LPAR1PLA2G2ACYP3A4 | |
| SCHEMBL23631717 | 0.85 | ITPR3 (0.49) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL10177948 | 0.83 | LPAR3 (0.45) | LPAR3LPAR2LPAR1PLA2G2ACYP3A4 | |
| SCHEMBL12583935 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026421-A1 | METHODS FOR CAPTURING LONG POLYNUCLEOTIDES FOR SEQUENCING SPECIFIC GENOMIC REGIONS | GENERATION BIOTECH, LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240026421-A1 | METHODS FOR CAPTURING LONG POLYNUCLEOTIDES FOR SEQUENCING SPECIFIC GENOMIC REGIONS | GENERATION BIOTECH, LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11840688-B2 | Compositions and methods for inhibiting gene expression of Hif2alpha | Arrowhead Pharmaceuticals, Inc. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11821023-B2 | Method for capturing long polynucleotides for sequencing specific gnomic regions | GENERATION BIOTECH, LLC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11821023-B2 | Method for capturing long polynucleotides for sequencing specific gnomic regions | GENERATION BIOTECH, LLC (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230348904-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS | BANK OF AMERICA, N.A. | 2023-11-02 | — | — | US | disclosed |
| US-20230338555-A1 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230310486-A1 | CONJUGATED OLIGONUCLEOTIDE COMPOUNDS, METHODS OF MAKING AND USES THEREOF | E-THERAPEUTICS PLC (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230295628-A1 | NUCLEIC ACID COMPLEX | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20100323967-A1 | RNA Antagonist Compounds for the Modulation of MCL-1 | SANTARIS PHARMA A/S (DK) | 2010-12-23 | — | — | US | disclosed |
| US-20100317714-A1 | COMPLEX MOLECULE INTERFERING THE EXPRESSION OF TARGET GENES AND ITS PREPARING METHODS | SUZHOU RIBO LIFE SCIENCE CO., LTD (CN) | 2010-12-16 | — | — | US | disclosed |
| US-20100298410-A1 | MICROMIRs | SANTARIS PHARMA A/S | 2010-11-25 | — | — | US | disclosed |
| US-20100234451-A1 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR | ENZON PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100028873-A1 | METHODS AND MEANS FOR NUCLEIC ACID SEQUENCING | GENIZON BIOSCIENCES, INC. (CA) | 2010-02-04 | — | — | US | disclosed |
| US-20090298916-A1 | Pharmaceutical compositions for treatment of microRNA related diseases | SANTARIS PHARMA A/S (DK) | 2009-12-03 | — | — | US | disclosed |
| US-20090203137-A1 | COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2009-08-13 | — | — | US | disclosed |
| US-20090192110-A1 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION | SANTARIS PHARMA A/S | 2009-07-30 | — | — | US | disclosed |
| US-20090181916-A1 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR | SANTARIS PHARMA A/S (DK) | 2009-07-16 | — | — | US | disclosed |
| US-20090143326-A1 | MICROMIRs | SANTARIS PHARMA A/S (DK) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143326-A1 | MICROMIRs | TRDMT1, METTL16, MTNR1A | LPAR3 613/4885LPAR2 1163/4885LPAR1 1434/4885 |
| US-20090192110-A1 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION | PIK3CA, PIK3R4, PIK3R5 | LPAR3 543/4885LPAR2 937/4885LPAR1 761/4885 |
| US-20090203137-A1 | COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION | CTNNB1, CTNNA1, WNT1 | LPAR3 350/4885LPAR2 929/4885LPAR1 602/4885 |
| US-20090181916-A1 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR | AR, ESRRB, ESRRA | LPAR3 15/4885LPAR2 29/4885LPAR1 19/4885 |
| US-20100234451-A1 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR | AR, ESRRB, LHCGR | LPAR3 16/4885LPAR2 31/4885LPAR1 21/4885 |
| US-20230295628-A1 | NUCLEIC ACID COMPLEX | POLRMT, SNRPE, FABP7 | LPAR3 146/4885LPAR2 93/4885LPAR1 145/4885 |
| US-20230338555-A1 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | DCLRE1B, RNASE1, LNPEP | LPAR3 800/4885LPAR2 753/4885LPAR1 810/4885 |
| US-11840688-B2 | Compositions and methods for inhibiting gene expression of Hif2alpha | EPAS1, HIF1AN, EGLN2 | LPAR3 1310/4885LPAR2 538/4885LPAR1 1570/4885 |
| US-20230310486-A1 | CONJUGATED OLIGONUCLEOTIDE COMPOUNDS, METHODS OF MAKING AND USES THEREOF | DCLRE1B, POLRMT, POLI | LPAR3 247/4885LPAR2 777/4885LPAR1 698/4885 |
| US-20090298916-A1 | Pharmaceutical compositions for treatment of microRNA related diseases | NSUN3, TRDMT1, NSUN2 | LPAR3 418/4885LPAR2 576/4885LPAR1 519/4885 |
| US-20100317714-A1 | COMPLEX MOLECULE INTERFERING THE EXPRESSION OF TARGET GENES AND ITS PREPARING METHODS | DCLRE1B, RNASE1, AGO2 | LPAR3 1764/4885LPAR2 1784/4885LPAR1 1843/4885 |
| US-20100323967-A1 | RNA Antagonist Compounds for the Modulation of MCL-1 | MCL1, NSUN2, MCTS1 | LPAR3 560/4885LPAR2 815/4885LPAR1 450/4885 |
| US-20100298410-A1 | MICROMIRs | TRDMT1, METTL16, MTNR1A | LPAR3 613/4885LPAR2 1163/4885LPAR1 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.